Search results for "Formulary"
showing 5 items of 5 documents
OHP-041 Formulary Decision-Making For Biosimilars: Considerations For Hospital Pharmacists
2013
Background It has been 6 years since the first biosimilar was approved for use in the European Union (EU). Given the likelihood that biosimilar monoclonal antibodies will be approved in Europe in the near future, it is timely to review the formulary selection criteria for biologicals and biosimilars. The European Medicines Agency (EMA) has issued guidelines that define the regulation of biosimilars in Europe and recommend approaches to establish biosimilarity. However, several questions regarding the assessment of biosimilars for formulary inclusion remain unanswered, including those related to manufacturing and drug supply. Purpose To aid hospital pharmacists in developing evaluation crite…
5PSQ-096 Hazard vulnerability analysis to evaluate the risk of drug shortages according to therapeutic class
2020
Background and importance Drug shortages are a critical challenge for the public health system, as highlighted by EAHP’s position paper. They have a negative impact on quality and efficiency of patient care. Aim and objectives The aim of our study was the application of a revised hazard vulnerability analysis (HVA) to assess which therapeutic classes of drugs are at greatest risk of shortages. Material and methods In September 2019, we analysed the drugs present in our hospital therapeutic formulary and checked which ones were included in the Italian Medicines Agency shortages list: 43 drugs were found. For each drug, we assigned a score using a revised HVA which consists of three macro are…
Awareness and understanding of cancer immunotherapy in Europe.
2014
3053 Background: Use of immunotherapies in the treatment of cancer is growing and a range of new immunotherapeutic strategies are being evaluated. It is important that healthcare providers (HCP) understand these treatments and how they compare with and may complement established therapies. As part of the activities of the POINT expert group, we commissioned a survey of current awareness, attitudes and perceptions of cancer immunotherapy in Europe. Methods: From August-September 2011, 426 healthcare professionals (HCPs: oncologists, surgeons and oncology nurses) from France, Germany, Italy, Spain and the UK (~85 respondents/country) completed online interviews. Representatives of patient ad…
2SPD-025 Application of hazard vulnerability analysis to evaluate the risk level of medicine shortages
2020
Background and importance Drug shortages have become a worldwide phenomenon which has repercussions on patient care and on the hospital’s budget. Aim and objectives The aim of our study was to assess the risk of shortages of drugs included in our hospital therapeutic formulary (HTF), for which there is shortage reporting, using a hazard vulnerability analysis (HVA). Material and methods We performed an HVA on 43 drugs in our HTF, which were also included in the Italian Medicines Agency list of shortages. The HVA used to assign the risk of shortage (ROS) included three macro areas: probability that the shortages will occur based on shortages in the past 2 years; magnitude factors which incre…
Il percorso (incerto) della c.d. web tax italiana tra modelli internazionali ed eurounitari di tassazione della digital economy
2019
L’articolo analizza gli aspetti essenziali dell’evoluzione delle strategie di tassazione delle imprese della digital economy, tanto a livello internazionale, quanto a livello eurounitario, per concludere, poi, con un’analisi dell’art. 1, commi 35 e segg., della Legge 30 dicembre 2018 n. 145 (legge di bilancio 2019), che ha introdotto, nel nostro sistema una vera e propria imposta sulle imprese che operano nel settore digitale, denominata “imposta sui servizi digitali” (ISD). Si osserva, a riguardo, che nel comparto della digital economy, quanto all’aspetto della tassazione, è possibile individuare tre diversi approcci. Il primo attribuisce particolare rilievo alla c.d. “presenza economica s…